Inactive Instrument

Inotek Pharmaceuticals Corp Stock price Nasdaq

Equities

US45780V1026

Biotechnology & Medical Research

End-of-day quote Nasdaq
- 0.00% Intraday chart for Inotek Pharmaceuticals Corp
Sales 2024 * 23.11M 0 Sales 2025 * 192M 0 Capitalization 2.44B 0
Net income 2024 * -262M - Net income 2025 * -217M - EV / Sales 2024 * 98.1 x
Net cash position 2024 * 172M 0 Net cash position 2025 * 39.19M 0 EV / Sales 2025 * 12.5 x
P/E ratio 2024 *
-10.1 x
P/E ratio 2025 *
-14.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.49%
More Fundamentals * Assessed data
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO MT
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer CI
Rocket Pharmaceuticals, Inc. Announces Executive Appointments CI
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating MT
Rocket Pharmaceuticals Q4 Loss Narrows MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : S&P 500 Futures -2- DJ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi DJ
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I) CI
Transcript : Rocket Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Certain Common Stock of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Warrants of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Restricted Stock Units of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Stock Options of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
More news
Managers TitleAgeSince
Chief Executive Officer 49 18-01-03
President 46 18-01-03
Chief Tech/Sci/R&D Officer 60 15-12-31
Members of the board TitleAgeSince
Director/Board Member 77 18-01-03
Director/Board Member 57 15-12-31
Director/Board Member 63 14-07-31
More insiders
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Rocket Pharmaceuticals, Inc.
  4. Stock Inotek Pharmaceuticals Corp - Nasdaq